Prosecution Insights
Last updated: November 17, 2026
Application No. 17/998,432

SLOW RELEASE PLASMINOGEN ACTIVATOR FORMULATION FOR USE IN THE TREATMENT OF THROMBOTIC OR HAEMORRHAGIC DISEASE

Non-Final OA §103§112
Filed
Nov 10, 2022
Priority
May 11, 2020 — EU 20305462.2 +1 more
Examiner
FAN, LYNN Y
Art Unit
1759
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Op2Lysis
OA Round
3 (Non-Final)
48%
Grant Probability
Moderate
3-4
OA Rounds
97%
With Interview

Examiner Intelligence

Grants 48% of resolved cases
48%
Career Allowance Rate
234 granted / 492 resolved
-17.4% vs TC avg
Strong +50% interview lift
Without
With
+49.5%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
75 currently pending
Career history
544
Total Applications
across all art units

Office Action

§103 §112
DETAILED ACTION The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on July 24, 2026 has been entered. Claims 2-6 and 10 have been canceled. Claims 1, 7-9 and 11-20 are pending, Claims 8, 11-15 and 19-20 have been withdrawn, and Claims 1, 7, 9, and 16-18 have been considered on the merits, insofar as they read on the elected species of a double mutant W235R and R275S tPA. All arguments have been fully considered. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 7, 9, and 16-18 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Claim 1, the recitation of “a thermoreversible polymer comprising poloxamer 407” is indefinite because when poloxamer 407 undergoes a chemical reaction with another compound, it is no longer poloxamer 407, and the limitation recites “comprising”. Therefore, it is unclear how the limitation “a thermoreversible polymer comprising poloxamer 407” is being claimed. In addition, the recitation of “a composition comprising: a nanoparticle … suspended in said thermoreversible polymer” is indefinite because the term “suspended in” implies that the only solvent is the thermoreversible polymer. However, the limitation recites “comprising”. For instance, does adding water read on the limitation “suspended in said thermoreversible polymer” or not? Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim 1 is rejected under 35 U.S.C. 103 as being unpatentable over Ingber et al (US 2015/0147276 A1; 5/28/2015.) in view of Salatin et al (RPS. 2017;12(1):1-14.). The instant claims recite a composition comprising: a nanoparticle comprising a plasminogen activator precipitated with a poloxamer 188, and a thermoreversible polymer comprising poloxamer 407, wherein said nanoparticle is suspended in said thermoreversible polymer. The limitation of “precipitated with a poloxamer 188” is regarded as a product-by-process limitation. Therefore, claim 1 is interpreted as a composition comprising a nanoparticle comprising a plasminogen activator, and a thermoreversible polymer comprising poloxamer 407, wherein said nanoparticle is suspended in said thermoreversible polymer. Ingber teaches compositions (para 0002) comprising nanoparticles (para 0027) comprise plasminogen activator (para 0143) and poloxamer 407 (a thermoreversible polymer) (para 0075). Ingber does not teach said nanoparticle is suspended in said thermoreversible polymer (claim 1). However, Ingber does teach said compositions comprise nanoparticles comprise plasminogen activator and poloxamer 407. Salatin teaches a composition comprising a nanoparticle, and poloxamer 407, wherein said nanoparticle is suspended in said thermoreversible polymer (p.3 col right – para 1-2). Salatin teaches poloxamer 407 has been exploited for use in the preparation of nanoparticles as emulsifying or solubilizing agent (p.2 col right – para 1). Thus, before the effective filing date of the claimed invention, it would have been obvious to one of ordinary skill in the art to suspend nanoparticles in poloxamer 407, since Ingber and Salatin both disclose a composition comprising a nanoparticle and poloxamer 407, and Salatin discloses that poloxamer 407 ensures nanoparticle stability (p.2 col right – para 1). Moreover, before the effective filing date of the claimed invention, one of ordinary skill in the art would have been motivated by the cited reference and routine practice to suspend nanoparticles in poloxamer 407 with a reasonable expectation for successfully obtaining a composition. Claims 7 and 16-17 are rejected under 35 U.S.C. 103 as being unpatentable over Ingber et al (US 2015/0147276 A1; 5/28/2015.) in view of Salatin et al (RPS. 2017;12(1):1-14.) as applied to claim 1 above, further in view of Dorraj et al (IJPR. 2015;14(2):347-358.). References cited above do not teach the claimed poloxamer 407 concentration (claims 7 and 16-17). However, Ingber and Salatin do teach a composition comprises poloxamer 407, and Salatin does teach poloxamer 407 is used as a stabilizer. Dorraj teaches poloxamer 407 aqueous systems as a prolonged release system for injectable nanoparticles (p.348 col right – para 4), wherein one of the most important factors in ability of poloxamer 407 to form a gel at physiological temperature is its concentration, poloxamer concentration of 20% w/v is used based on the manufacturer suggestion (p.350 col right – para 5). Thus, before the effective filing date of the claimed invention, it would have been obvious to one of ordinary skill in the art to optimize the concentration of poloxamer 407 as a matter of routine experimentation, since Dorraj discloses that one of the most important factors in ability of poloxamer 407 to form a gel at physiological temperature is its concentration, and that the concentration of stabilizer (poloxamer 407) is obtained from investigating the effects of surfactant on the size and foaming of the system (p.349 col left – para 1). Generally, differences in concentration will not support patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration is critical. (MPEP 2144.05 II) Moreover, before the effective filing date of the claimed invention, one of ordinary skill in the art would have been motivated by the cited reference and routine practice to incorporate an optimized amount of poloxamer 407 with a reasonable expectation for successfully obtaining a composition. Claims 9 and 18 are rejected under 35 U.S.C. 103 as being unpatentable over Ingber et al (US 2015/0147276 A1; 5/28/2015.) in view of Salatin et al (RPS. 2017;12(1):1-14.) as applied to claim 1 above, further in view of Vivien et al (WO 2013/034710 A1; 3/14/2013.). References cited above do not teach the claimed plasminogen activator (claims 9 and 18). However, Ingber does teach said compositions can be used for treating thrombotic disorders and internal hemorrhage (Abstract), and said compositions comprise plasminogen activator, wherein said plasminogen activator includes hybrids, fragments and mutants (para 0143). Vivien teaches mutated plasminogen activators for treating thrombotic and haemorrhagic diseases (p.1 line 5-6), wherein said mutant is a double mutation W253R and R275S (a plasminogen activator) (p.11 line 4-5, line 15 line 22-23). Note: Sequence is listed in Search results filed on 10/6/2025, 20251006_100604_us-17-998-432-1.rag file, Result 1, see below. PNG media_image1.png 1948 816 media_image1.png Greyscale Thus, before the effective filing date of the claimed invention, it would have been obvious to one of ordinary skill in the art to incorporate plasminogen activator that is a double mutant W253R and R275S tPA having a sequence set forth as SEQ ID NO: 1, since Ingber and Vivien both disclose compositions for treating thrombotic disorders and hemorrhage, Ingber discloses compositions comprise mutated plasminogen activator, and Vivien discloses compositions comprise a double mutation W253R and R275S plasminogen activator having a sequence set forth as SEQ ID NO: 1. Moreover, before the effective filing date of the claimed invention, one of ordinary skill in the art would have been motivated by the cited reference to incorporate plasminogen activator that is a double mutant W253R and R275S tPA having a sequence set forth as SEQ ID NO: 1, with a reasonable expectation for successfully obtaining a composition. Response to Arguments Applicant argues that the purpose of Ingber et al. differs completely from the present invention, that Ingber would not have motivated a person of ordinary skill in the art to replace its stimulus-responsive, surface-functionalized PLGA aggregate system with a plasminogen activator-poloxamer nanoprecipitate suspension in P407, nor does Ingber provide a reasonable expectation that such a nanoprecipitation-first formulation would address the release and activity problems associated with direct incorporation of a protease into a thermoreversible polymer. These arguments are not found persuasive because rejected claims are directed to a composition. The limitation of “precipitated with a poloxamer 188” as amended in claim 1 is regarded as a product-by-process limitation. Ingber does teach a composition comprising a nanoparticle comprises plasminogen activator and poloxamer 407, and Salatin does teach a nanoparticle is suspended in poloxamer 407, and poloxamer 407 ensures nanoparticle stability. Applicant argues that Giuliano does not cure this deficiency, and that Vivien does not teach or suggest precipitating that plasminogen activator with a poloxamer to form a nanoparticle, nor suspending that nanoparticle in a thermoreversible polymer comprising P407. However, these arguments are moot in light of the new rejections above in view of applicant’s amendments. Applicant’s Affidavit submitted on 7/16/2026 is acknowledged and reviewed. However, applicant’s Affidavit is not commensurate in scope with the claims. The Affidavit did not define nanoparticle as well as poloxamer solution. In addition, data supporting unexpected results is missing in the Affidavit. Finally, please note that rejected claims are directed to a composition, not a process. Conclusion No claims are allowed. Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to LYNN Y FAN whose telephone number is (571)270-3541. The examiner can normally be reached on M-F 7am-4pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Curtis Mayes can be reached on (571)272-1234. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Lynn Y Fan/ Primary Examiner, Art Unit 1759
Read full office action

Prosecution Timeline

Show 2 earlier events
Apr 13, 2026
Response Filed
May 27, 2026
Final Rejection mailed — §103, §112
Jul 16, 2026
Response after Non-Final Action
Jul 16, 2026
Response after Non-Final Action
Jul 24, 2026
Request for Continued Examination
Jul 27, 2026
Response after Non-Final Action
Oct 02, 2026
Non-Final Rejection mailed — §103, §112
Nov 16, 2026
Interview Requested

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778994
AGENT FOR REGULATING FEMALE HORMONE SECRETION AND AGENT FOR ALLEVIATING UNPLEASANT SYMPTOMS
4y 9m to grant Granted Nov 03, 2026
Patent 12782273
MOLECULAR PROBES FOR MAPPING BIOLOGICAL ACTIVITY
2y 9m to grant Granted Nov 03, 2026
Patent 12773433
COMPOSITION OF LACTIC ACID BACTERIUM FOR USE IN PREVENTING OR TREATING RETT SYNDROME
4y 2m to grant Granted Oct 27, 2026
Patent 12773427
MULTILAYERED BLOOD PRODUCT
2y 6m to grant Granted Oct 27, 2026
Patent 12747463
Enhanced Sophorolipid Derivatives
4y 1m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
48%
Grant Probability
97%
With Interview (+49.5%)
High
PTA Risk
Based on 492 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month